Baxfendy (Baxdrostat) Gains FDA Approval as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
Baxfendy (baxdrostat) has been approved by the FDA as the first and only aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension. The BaxHTN Phase III trial showed significant blood pressure reduction and a favorable safety profile, offering a new avenue for hypertensiv